Noura Elsedawy is an Oncology physician affiliated with St. Jude Children's Research Hospital. OpenAlex indexes 9 publications with 475 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
880 Madison Ave
Memphis, TN 381033409
Telephone
901-545-6262Provider last certified this registry record 22 Sept 2020.
Industry payments
17 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20253 payments
- PFIZER INC.Program year20253 payments
- Janssen Biotech, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
59.7%Thalidomide Analog41.8%Revlimid100%Part D<11 patientsProteasome Inhibitor17.9%Ninlaro100%Part D<11 patientsMusculoskeletal
40.3%RANK Ligand Inhibitor20.9%Xgeva100%Part D<11 patientsBisphosphonate19.4%Zoledronic Acid100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network
2026 - NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025
Journal of the National Comprehensive Cancer Network
2025 - CT-654: From Response Rates to Toxicity Profiles: A Meta-Analysis of Two FDA Approved CAR-T Therapies in Relapsed/Refractory Multiple Myeloma—2025
Clinical Lymphoma Myeloma & Leukemia
2025 - POSTER: CT-654 From Response Rates to Toxicity Profiles: A Meta-Analysis of Two FDA Approved CAR-T Therapies in Relapsed/Refractory Multiple Myeloma—2025
Clinical Lymphoma Myeloma & Leukemia
2025 - Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Jeffrey Towbin, MD
St. Jude Children's Research Hospital
Raul Ribeiro, MD
St. Jude Children's Research Hospital
Thomas Merchant, DO
St. Jude Children's Research Hospital
Alberto Pappo, MD
St. Jude Children's Research Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”